Pacific Biosciences California (PACB) Stock
Developer of long-read DNA sequencing systems and consumables. Here's the price, business snapshot, and what's worth knowing about Pacific Biosciences California in August 2026.
Pacific Biosciences of California, Inc. (PACB) develops long‑read DNA sequencing systems and consumables used in genomics research and translational science. Its platforms produce high‑accuracy long reads that help assemble complex genomes, call structural variants and support applications across human genetics, agricultural genomics and drug discovery. Revenue is driven by sales of instruments, recurring consumables, service agreements and software. With a market capitalisation of about $570.70m, PACB is a small‑cap, growth‑oriented company and its shares can be volatile. Key considerations for investors include product adoption, the recurring consumable revenue stream, competitive dynamics with short‑ and long‑read sequencing rivals, and the company’s pathway to sustainable profitability. Operational risks include execution on commercial roll‑out, supply‑chain constraints and R&D outcomes. This is general educational information only and not personal investment advice; values can rise and fall and past performance does not predict future returns.
